

## ACIONT, INC.

### Company Information

Company Name  
ACIONT, INC.

Address  
350 WEST 800 NORTH, STE 320  
SALT LAKE CITY, UT, 84103-  
Phone  
1 801-359-3461

URL  
n/a  
DUNS  
n/a

Number of Employees  
n/a  
Hubzone Owned:  
N

Minority Owned:  
N  
Woman Owned:  
N

### Award Totals

```
jQuery(document).ready( function() { (function ($) { var program = ['SBIR Phase I', 'SBIR Phase II',  
'STTR Phase I', 'STTR Phase II']; var programCount = [{ "y":3,"amount":"433,703.00"}, {"y":1,"amount  
":"2,029,592.00"}, {"y":0,"amount":"0.00"}, {"y":0,"amount":"0.00"}]; //var programAmount =  
[433,703.00,2,029,592.00,0.00,0.00]; var title = 'Firm Award by Program and Phase'; var titleFormat  
= 'Count: {point.y:0f}'; var titleFormatAmount = 'Amount: ${point.y:2f}'; var charWidth =  
$('#award-totals-chart-count').width(); charWidth -= 120; $('#award-totals-chart-  
count').highcharts({ chart: { type: 'column' }, title: { text: title }, xAxis: { categories: program,  
labels: { rotation: -45, style: { fontSize: '13px', fontFamily: 'Verdana, sans-serif' } } }, yAxis: { min:  
0, title: { text: 'Awards' } }, legend: { enabled: false }, tooltip: { formatter: function() { return '' +  
this.x + '
```

```
' + 'Award Count: '+ this.y +'  
' + 'Award Amount: $'+ this.point.amount +''; } }, series: [{ name: 'Program/Phase', data:  
programCount, dataLabels: { enabled: false, rotation: -90, color: '#FFFFFF', align: 'right', //format:  
'{point.y:0f}', // no decimal y: 10, // 10 pixels down from the top style: { fontSize: '13px', fontFamily:  
'Verdana, sans-serif' } } } ] }); $("#award_total_table").trigger('click'); })(jQuery); });
```

- [Award Table](#)
- [Award Chart](#)

PROGRAM/PHASE  
AWARD AMOUNT (\$)

## NUMBER OF AWARDS

SBIR Phase I

\$433,703.00

3

SBIR Phase II

\$2,029,592.00

1

**Award List**

1.

[NON-INVASIVE BLOOD PHENYLALANINE MONITOR](#)

Amount: \$159,509.00

DESCRIPTION (provided by applicant): Phenylketonuria (PKU) is a genetic deficiency of phenylalanine hydroxylase (PAH). Without PAH, the patient with PKU cannot metabolize phenylalanine (PHE) to tyros ...

SBIR Phase I 2002 Department of Health and Human Services

2.

[IMPROVED NON-INVASIVE BLOOD GLUCOSE MONITORING DEVICE](#)

Amount: \$140,992.00

The accurate measurement of blood glucose concentration is important in the management of diabetes. Current methods of glucose monitoring involve piercing the skin and collecting blood samples for ana ...

SBIR Phase I 2002 Department of Health and Human Services

3.

[Non-Invasive Drug Delivery to Treat Posterior Uveitis](#)

Amount: \$133,202.00

Intermediate and posterior uveitis cause 10% of blindness in the U.S. The mainstay of therapy is to eradicate the infectious cause and to quell the inflammation with corticosteroids or immunosuppressa ...

SBIR Phase I 2004 Department of Health and Human Services

4.

[Non-Invasive Treatment for Uveitis](#)

Amount: \$2,029,592.00

DESCRIPTION (provided by applicant): The aim of this innovative proposal is to commercialize a non-invasive topical product that treats uveitis which is safe and easy to administer. Uveitis is the thi ...

SBIR Phase II 2013 Department of Health and Human Services

